Antonio Galisteo-Tapia

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

A Drug-Gated, Modular STAb-T Immunotherapy With External Control.

A Drug-Gated, Modular STAb-T Immunotherapy With External Control.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 22, 2026

Generation and functional evaluation of bispecific T cell engaging antibodies.

Generation and functional evaluation of bispecific T cell engaging antibodies.

Journal: Methods in cell biology

Published: October 17, 2025

mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors.

mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors.

Journal: Frontiers in immunology

Published: August 12, 2025

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation.

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation.

Journal: Frontiers in immunology

Published: September 10, 2024

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.

Journal: Oncoimmunology

Published: April 16, 2024

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Journal: Science translational medicine

Published: February 14, 2024

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.

Journal: Journal of hematology & oncology

Published: June 05, 2023

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Journal: Oncoimmunology

Published: April 28, 2023

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.

Journal: Theranostics

Published: December 03, 2022

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.

Journal: Oncoimmunology

Published: February 14, 2022

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.

Journal: iScience

Published: February 04, 2022

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Journal: Cancer immunology research

Published: October 07, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026